Peptide RX

back to claim graph

proof receipt / fold

GRIN2B WT

Structure prediction with public confidence context.

grade B status complete receipt df981600ccce proof 67%

what this node claims

GRIN2B WT

Structure prediction with public confidence context.

Open source surface

vertical proof spine

  1. 01 GRIN2B WT fold / grade B / 54% 3 debt
  2. 02 AlphaFold metrics / GRIN2B alphafold metric / grade B / 70% 1 debt
  3. 03 Initial digest — GRIN2B finding / grade C / 47% 1 debt
  4. 04 fold.complete timeline event / grade C / 55%
  5. 05 GRIN2B target / grade B / 70% 1 debt

evidence / risk instrument

47%
thin proof
structure evidence gates risk export lineage 47
visible debt pressure 50%
61%structureusable
pLDDT 60.7
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
67%lineageusable
incomplete spine

proof completeness

67% missing candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence band
low
confidence pct
60.7
coverage available
false
gene
GRIN2B
has structure
true
pae available
false
plddt avg
60.7
sequence length
0
variant
WT

AlphaFold metrics visual

Low-confidence regions present

60.7

1484 residues / min 24.03 / max 96.0 / source alphafold db

PAE matrix for linked target
Very high 17.8% 264 residues / >=90
Confident 29.2% 434 residues / 70-89
Low 8.8% 131 residues / 50-69
Very low 44.1% 655 residues / <50

weak structural context; downstream claims should be conservative

Near-complete coverage / observed 1484 of 1484 residues.

  • residues 845-1484 / mean 33.4
  • residues 1-32 / mean 42.87
  • residues 581-600 / mean 52.73
  • residues 44-58 / mean 60.07
proof debt register

Visible limits, not hidden cleanup.

50%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low computational-only status add independent evidence, challenge result, or witness review before strengthening
low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing PAE/context where AlphaFold DB is not linked attach pLDDT series, PAE matrix, or coverage evidence
high low evidence grade attach graded finding with source-linked evidence
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing PAE/context where AlphaFold DB is not linked medium visible weakens attach pLDDT series, PAE matrix, or coverage evidence
low evidence grade high blocks weakens attach graded finding with source-linked evidence
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

target has structure prediction target:1b5f0efe-ab68-4bed-9fe3-3dbae6604183 -> fold:dc16af81-4f81-4efe-9fab-d9d95327c37b folds_to / B / 0.607

what it supports

measured by AlphaFold confidence context fold:dc16af81-4f81-4efe-9fab-d9d95327c37b -> alphafold_metric:dc16af81-4f81-4efe-9fab-d9d95327c37b measured_by / B / 0.607
evidence finding attached fold:dc16af81-4f81-4efe-9fab-d9d95327c37b -> finding:947550eb-c2aa-49b3-9bab-2539ced734f6 supports / C / 0.6
timeline records state change fold:dc16af81-4f81-4efe-9fab-d9d95327c37b -> timeline_event:27 records / C / 0.5

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.